FTC Requires Ascension Divestitures in $3.9B AmSurg Deal

Why It Matters

The conditional approval lets Ascension expand its outpatient footprint while preserving competition, affecting pricing and access for millions of patients. It also signals heightened regulatory scrutiny of health‑system consolidations amid a shift toward outpatient care.

Key Takeaways

• FTC mandates sale of seven AmSurg centers to preserve competition
• Six divested facilities will be sold to SCA Health, owned by Optum
• Deal adds 250+ surgery centers, bringing Ascension to 300+ nationwide
• Ascension expects acquisition to close “near future” after compromise
• Monitor will enforce compliance and restrict future purchases in those markets

Pulse Analysis

The Catholic health system Ascension has been pursuing a strategic pivot from hospital‑centric operations to a broader outpatient portfolio. Its $3.9 billion bid for AmSurg, a network of more than 250 ambulatory surgery centers across 34 states, would raise Ascension’s total to over 300 centers in 35 states, positioning it as one of the nation’s largest outpatient surgical operators. The move reflects a sector‑wide response to declining inpatient volumes, rising cost pressures, and growing consumer demand for convenient, lower‑cost procedures performed outside traditional hospitals.

The Federal Trade Commission intervened by issuing a consent order that requires Ascension to divest seven AmSurg facilities in markets where the combined entity would dominate ambulatory surgery services. Six of the centers will be transferred to SCA Health, the Optum‑owned arm of UnitedHealth, while the seventh will go to Florida Gastroenterology Center. By carving out these locations, the FTC aims to preserve price competition and prevent potential reductions in innovation. A court‑appointed monitor will oversee the divestitures, enforce operational continuity, and block any further acquisitions in the same metros for ten years.

While the divestiture compromise clears a major regulatory hurdle, it also underscores the heightened scrutiny health‑system mergers now face. Analysts view the AmSurg acquisition as a lifeline for Ascension, which has wrestled with operating losses and a costly 2024 cyberattack. Expanding into the outpatient arena promises higher margins and steadier cash flow, but success will depend on integrating the new centers without inflating prices. The FTC’s conditional approval may set a precedent for future deals, encouraging sellers to pre‑emptively address antitrust concerns to accelerate closing timelines.